Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-28T05:23:57.711Z Has data issue: false hasContentIssue false
  • English
  • Français

Severe laryngitis following chronic anabolic steroid abuse

Published online by Cambridge University Press:  14 May 2007

S Ray ,
A Masood ,
J Pickles  and
I Moumoulidis
Get access Rights & Permissions [Opens in a new window]

Abstract

The effects of anabolic steroids on the quality of voice have been well documented; however, no study has established significant structural changes in the larynx as a direct result of anabolic steroid use. We report a unique case of a 47-year-old male smoker and professional body builder who presented with progressive stridor and hoarseness following abuse of anabolic steroids over a period of two years. Conservative management failed to resolve his symptoms and a planned tracheostomy was performed to secure his airway. Subsequently he was treated with multiple laser resections and eventually decannulated. No case of severe laryngitis in association with anabolic steroid usage has been reported previously in the literature.

Keywords

LaryngitisSteroidsAnabolic AgentsTracheostomy
Type
Review Article
Information
The Journal of Laryngology & Otology , Volume 122 , Issue 3 , March 2008 , pp. 230 - 232
Copyright
Copyright © JLO (1984) Limited 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1 Baker, J. A report on alterations to the speaking and singing voices of four women following hormonal therapy with virilizing agents. J Voice 1999;13:496–50710.1016/S0892-1997(99)80005-8CrossRefGoogle Scholar
2 Gerritsma, EJ, Brocaar, MP, Hakkesteegt, MM, Birkenhager, JC. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Deca-Durabolin). The effects of medication for one year. Clin Otolaryngol 1994;19:79–8410.1111/j.1365-2273.1994.tb01153.xCrossRefGoogle Scholar
3 Spooner, JB. Classification of side effects to danazol therapy. J Int Med Res 1997;5:15–17Google Scholar
4 Epstein, R, Bridger, M. Voice changes after treatment with danazol. Br Med J 1983;287:130810.1136/bmj.287.6401.1308-cCrossRefGoogle Scholar
5 Hardt, W. Clinically relevant side effects of danazol [in German]. Orynakol Prax 1987;11:457–70Google Scholar
6 Boothroyd, CV, Lepre, F. Permanent voice change resulting from danazol therapy. Aus N Z J Obstet Gynaecol 1990;30:275–610.1111/j.1479-828X.1990.tb03232.xCrossRefGoogle ScholarPubMed
7 Wilson, JD. Androgen abuse by athletes. Endocrinol Rev 1998;2:181–99Google Scholar
8 Barbieri, RL, Evans, S, Kistner, RW. Danazol in the treatment of endometriosis: Analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37:737–4610.1016/S0015-0282(16)46331-4CrossRefGoogle Scholar
9 Wardle, PG, Whitehead, RA, Mills, P. Non-reversable and wide ranging voice changes after treatment with danazol. Br Med J 1983;287:94610.1136/bmj.287.6397.946CrossRefGoogle ScholarPubMed
10 Talaat, M, Talaat, AM, Kelada, I, Angelo, A, Elwany, S, Thabet, H. Histologic and histochemical study of anabolic steroids on the female larynx. Ann Otol Rhinol Laryngol 1987;96:468–7110.1177/000348948709600423CrossRefGoogle ScholarPubMed